Compare Msci Inc (MSCI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Pfizer Inc — how do they compare? Msci Inc trades at $562.19 (market cap $40.38B), while Pfizer Inc trades at $27.77 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 4× Msci Inc's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and Pfizer Inc for 158 Days on average.
| MSCI | PFE | |
|---|---|---|
Market Cap | $40.38B | $159.59B |
Volume | 414,140 | 30,937,010 |
Sector | Financials | Health |
52-Week High | $643.83 | $29.02 |
52-Week Low | $511.84 | $23.67 |
Typical Hold Time | 82 Days | 158 Days |
Enterprise Value | $46.54B | $211.09B |
Dividend Yield | 1.48% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $555.38, up 0.08% with neutral technical signals. The company demonstrates strong fundamentals with 2025 revenue of $3.13B and net income margin of 40.73%. Recent Q2 2026 earnings slightly missed expectations at $4.94 EPS versus $4.99 expected, though Q1 and Q4 2025 beat estimates. Analyst consensus remains strongly bullish with 74% buy ratings and $701.71 price target, representing 26% upside potential. The stock shows consistent revenue growth from $2.2B in 2022 to $3.1B in 2025.
MSCI presents a compelling investment case with premium valuation (P/E 30.37) justified by strong profitability and market leadership. Key risks include high debt levels ($4.51B long-term debt) and competitive pressures in financial data services. The upcoming Q3 2026 earnings report on October 20, 2026, will be crucial for validating growth trajectory. Institutional sentiment remains positive given the company's recurring revenue model and expansion into climate risk analytics through the First Street acquisition.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
